Back

A next generation CRISPR diagnostic tool to survey drug resistance in Human African Trypanosomiasis.

Anton, E. P.; Dujeancourt-Henry, A.; Rotureau, B.; Glover, L.

2024-09-17 infectious diseases
10.1101/2024.09.15.24313552 medRxiv
Show abstract

The WHO aims to eliminate the gambiense form of human African trypanosomiasis (HAT) by 2030. With the decline of reported cases, maintaining efficient epidemiological surveillance is essential, including the emergence of drug-resistant strains. We have developed new highly specific diagnostic tools using Specific High-Sensitivity Reporter Enzymatic UnLOCKing (SHERLOCK) technology for monitoring the presence of drug-resistant genotypes that (1) are already circulating, such as the AQP2/3(814) chimera providing resistance to pentamidine and melarsoprol, or (2) could emerge, such as TbCPSF3 (N232H), associated to acoziborole resistance in lab conditions. The melarsoprol - pentamidineAQP2/3(814) SHERLOCK assay detected RNA from both cultured parasites and field isolated strains from gHAT patients in relapse following treatment. The acoziborole CPSF3(SNV)SHERLOCK assay discriminated between wild-type CPSF3 RNA and CPSF3 with a single A-C mutation that confers resistance to acoziborole in vitro.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.